secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)
CIK:        0001335105
Form:       8-K
Filed at:   2023-09-27T23:59:59+00:00
Accession:  0001493152-23-033825
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lixte appoints Bas van der Baan as President and CEO; founder Kovach becomes Executive Chairman
--------------------------------------------------------------------------------

- Bastiaan van der Baan named President, CEO and Vice Chairman effective September 26, 2023.
- Founder John S. Kovach, M.D. becomes Executive Chairman, remains Chief Scientific Officer.
- Employment agreement: 3-year term, $150,000 annual salary, with discretionary bonus.
- Granted options to purchase 250,000 shares at $1.95, vesting quarterly over 3 years.
- van der Baan brings 20+ years biotech experience; previously Chief Clinical Officer at Agendia.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1335105/000149315223033825/0001493152-23-033825-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1335105/000149315223033825/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-033825

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer